Decoding the expression pattern of MUC3A in gastric adenocarcinoma: unveiling the key to successful immunotherapy

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca A Cancer J Clinicians. 2021;71(3):209–249. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Charalampakis N, Economopoulou P, Kotsantis I, et al. Medical management of gastric cancer: a 2017 update. Cancer Med. 2018;7(1):123–133. doi: 10.1002/cam4.1274
   PubMed Web of Science ®Google Scholar
• Bang Y-J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–697. doi: 10.1016/S0140-6736(10)61121-X
   PubMed Web of Science ®Google Scholar
• Young K, Smyth E, Chau I. Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma. Therap Adv Gastroenterol. 2015;8(6):373–383. doi: 10.1177/1756283X15592586
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4(5):e180013–e180013. doi: 10.1001/jamaoncol.2018.0013
   PubMed Web of Science ®Google Scholar
• Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707–723. doi: 10.1016/j.cell.2017.01.017
   PubMed Web of Science ®Google Scholar
• McGuckin MA, Lindén SK, Sutton P, et al. Mucin dynamics and enteric pathogens. Nature Rev Microbiol. 2011;9(4):265–278. doi: 10.1038/nrmicro2538
   PubMed Web of Science ®Google Scholar
• Jonckheere N, Skrypek N, Frénois F, et al. Membrane-bound mucin modular domains: from structure to function. Biochimie. 2013;95(6):1077–1086. doi: 10.1016/j.biochi.2012.11.005
   PubMed Web of Science ®Google Scholar
• Hattrup CL, Gendler SJ. Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol. 2008;70(1):431–457. doi: 10.1146/annurev.physiol.70.113006.100659
   PubMedGoogle Scholar
• Senapati S, Das S, Batra SK. Mucin-interacting proteins: from function to therapeutics. Trends Biochem Sci. 2010;35(4):236–245. doi: 10.1016/j.tibs.2009.10.003
   PubMed Web of Science ®Google Scholar
• Bhatia R, Gautam SK, Cannon A, et al. Cancer-associated mucins: role in immune modulation and metastasis. Cancer Metast Rev. 2019;38(1):223–236. doi: 10.1007/s10555-018-09775-0
   PubMed Web of Science ®Google Scholar
• Sotoudeh M, Shirvani SI, Merat S, et al. MSLN (mesothelin), ANTXR1 (TEM8), and MUC3A are the potent antigenic targets for CAR T cell therapy of gastric adenocarcinoma. J Cell Biochem. 2019;120(4):5010–5017. doi: 10.1002/jcb.27776
   PubMed Web of Science ®Google Scholar
• Klebanoff CA, Rosenberg SA, Restifo NP. Prospects for gene-engineered T cell immunotherapy for solid cancers. Nature Med. 2016;22(1):26–36. doi: 10.1038/nm.4015
   PubMed Web of Science ®Google Scholar
• Colovic N, Jurisic V, Terzic T, et al. Immunochemotherapy for bcl-2 and MUM-negative aggressive primary cutaneous B-cell non-Hodgkin’s lymphoma. Arch Dermatol Res. 2009;301(9):689–692. doi: 10.1007/s00403-009-0967-1
   PubMed Web of Science ®Google Scholar
• NCCN clinical practice guidelines in oncology, gastric cancer, (Version 2.2021). cited 2021 Apr 15 [Internet].
   Google Scholar
• Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging. Ca A Cancer J Clinicians. 2017;67(2):93–99. doi: 10.3322/caac.21388
   PubMed Web of Science ®Google Scholar
• Gross G, Eshhar Z. Therapeutic potential of T cell chimeric antigen receptors (CARs) in cancer treatment: counteracting off-tumor toxicities for safe CAR T cell therapy. Annu Rev Pharmacol Toxicol. 2016;56(1):59–83. doi: 10.1146/annurev-pharmtox-010814-124844
   PubMedGoogle Scholar
• Wang R, Fang D. Alterations of MUC1 and MUC3 expression in gastric carcinoma: relevance to patient clinicopathological features. J Clin Pathol. 2003;56(5):378–384. doi: 10.1136/jcp.56.5.378
   PubMed Web of Science ®Google Scholar
• Posey AD Jr, Clausen H, June CH. Distinguishing truncated and normal MUC1 glycoform targeting from tn-MUC1-specific CAR T cells: specificity is the key to safety. Immunity. 2016;45(5):947–948. doi: 10.1016/j.immuni.2016.10.015
   PubMed Web of Science ®Google Scholar
• Haas AR, Golden RJ, Litzky LA, et al. Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells. Mol Ther. 2023;31(8):2309–2325. doi: 10.1016/j.ymthe.2023.06.006
   PubMed Web of Science ®Google Scholar
• Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843–851. doi: 10.1038/mt.2010.24
   PubMed Web of Science ®Google Scholar
• Sadelain M. Chimeric antigen receptors: a paradigm shift in immunotherapy. Annu Rev Cancer Biol. 2017;1(1):447–466. doi: 10.1146/annurev-cancerbio-050216-034351
   Google Scholar
• Kim DH, Shin N, Kim GH, et al. Mucin expression in gastric cancer: reappraisal of its clinicopathologic and prognostic significance. Arch Pathol Lab Med. 2013;137(8):1047–1053. doi: 10.5858/arpa.2012-0193-OA
   PubMed Web of Science ®Google Scholar
• Zhang C-T, He K-C, Pan F, et al. Prognostic value of Muc5AC in gastric cancer: a meta-analysis. World J Gastroenterol. 2015;21(36):10453. doi: 10.3748/wjg.v21.i36.10453
   PubMed Web of Science ®Google Scholar
• Noh J, Park KB, Kwon OK. The prognostic value of postoperative tumor marker conversion for gastric cancer. Korean J Clin Oncol. 2020;16(2):119. doi: 10.14216/kjco.20018
   PubMedGoogle Scholar
• Jurisic V, Radenkovic S, Konjevic G. The Actual Role of LDH as Tumor Marker, Biochemical and Clinical Aspects. In: Scatena R, editor. Advances in Cancer Biomarkers. Advances in Experimental Medicine and Biology. Vol. 867. 2015. doi:10.1007/978-94-017-7215-0_8
   Google Scholar